Vedanta Biosciences Secures $60M to Advance Phase 3 VE303
CAMBRIDGE, Mass., August 6, 2026 Vedanta Biosciences announced it has secured $60 million in funding to accelerate development of...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
CAMBRIDGE, Mass., August 6, 2026 Vedanta Biosciences announced it has secured $60 million in funding to accelerate development of...
MOUNTAIN VIEW, Calif., ARLINGTON, Va., and LONDON, England, May 13, 2026 Osel Inc., in partnership with March of Dimes...
GHENT, Belgium | January 9, 2026 — MRM Health announced that the U.S. Food and Drug Administration (FDA) has...
